FindTrial
Sign In

Maraviroc 300 mg

DRUG6 trials

Sponsors

Abramson Cancer Center at Penn Medicine, University of California, Los Angeles, University Of Perugia, Hospital Universitario Infanta Leonor, Tel-Aviv Sourasky Medical Center

Conditions

AtherosclerosisCOVID-19Cardiovascular Risk FactorGraft-versus-host DiseaseHIV Infection With Other ConditionsHematologic MalignancyHematopoietic Stem Cell TransplantationInflammation

Phase 1

Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
CompletedNCT00948753
Abramson Cancer Center at Penn MedicineGraft-versus-host Disease, Hematopoietic Stem Cell Transplantation
Start: 2009-06-30End: 2011-04-30Updated: 2022-05-17

Phase 2

Phase II Maraviroc for GVHD Prevention
CompletedNCT01785810
Abramson Cancer Center at Penn MedicineHematologic Malignancy
Start: 2013-02-28End: 2018-07-12Updated: 2021-01-11
Maraviroc to Augment Rehabilitation Outcomes After Stroke
TerminatedNCT03172026
University of California, Los AngelesStroke
Start: 2019-08-01End: 2020-10-01Updated: 2021-08-03
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
TerminatedNCT04441385
Hospital Universitario Infanta LeonorCOVID-19
Start: 2020-06-26End: 2021-02-08Updated: 2022-03-11
Safety of Maraviroc for Post-stroke Depression
CompletedNCT05932550
Tel-Aviv Sourasky Medical CenterPost-stroke Depression
Start: 2020-08-04End: 2022-08-04Updated: 2023-07-06

Phase 4

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.
CompletedNCT03402815
University Of PerugiaAtherosclerosis, Cardiovascular Risk Factor, HIV Infection With Other Conditions +1
Start: 2015-01-01End: 2017-09-30Updated: 2018-01-23

Related Papers

Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial.
2024-06-063 citations
The G protein coupled receptor CCR5 in cancer.
2020-01-1017 citations
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
2012-07-01193 citations